Latest Administration News

Javelin Minerals has initiated a significant capital consolidation, reducing its share count by a factor of 31, and is introducing a facility to help small shareholders sell untradeable parcels post-consolidation.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

Imagion Biosystems reports encouraging findings from its Wayne State University collaboration, supporting a lower dose for its MagSense® HER2 imaging agent ahead of a planned FDA IND submission in Q4 2025.

TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.

Medibank is set to acquire Better Medical, a network of 61 GP clinics across four states, for approximately $159 million, enhancing its primary care footprint and preventive health initiatives.

Altech Batteries confirms the strategic importance of its AMPower Agreement, enabling immediate sales and cash flow, while detailing a recent $6 million capital raising and addressing trading compliance issues.

Almonty Industries reported a strong net income in Q3 2025, driven by a significant non-cash warrant gain, while advancing the ramp-up of its flagship Sangdong Mine amid rising tungsten demand.

LCL Resources Limited faces suspension from ASX trading due to failure to lodge a required periodic report on time, raising questions about the company’s compliance and operational transparency.

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

Eastern Metals is progressing its acquisition of Raptor Resources and has agreed to sell its Browns Reef Project, while planning a $4-5 million capital raise pending shareholder approval.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.